Your activity: 2 p.v.

Overview of biologic agents and kinase inhibitors in the rheumatic diseases

Overview of biologic agents and kinase inhibitors in the rheumatic diseases
Author:
Gerd R Burmester, MD
Section Editor:
Daniel E Furst, MD
Deputy Editor:
Philip Seo, MD, MHS
Literature review current through: Dec 2022. | This topic last updated: Jun 15, 2022.

INTRODUCTION — Advances in molecular biology, immunology, and drug development since the late 1990s have led to a variety of new treatment approaches to rheumatoid arthritis and other systemic inflammatory diseases associated with autoimmunity. The major biologic approaches in clinical use, including both medications made by molecular biologic techniques and small molecule kinase inhibitors, include agents that:

Interfere with cytokine function, signal transduction, or production

Inhibit the "second signal" required for T-cell activation

Deplete B cells

An overview of biologic agents, biosimilar medications with near identity to the original biologic agents, and small molecule kinase inhibitors used in the management of patients with rheumatic disorders is reviewed here. The role of cytokines in the immune system and in rheumatic disease pathogenesis, the management strategies for individual diseases, and a fuller discussion of the efficacy and safety of these agents are presented in detail separately (see "The adaptive cellular immune response: T cells and cytokines"). (See relevant disease-specific topic reviews.)

T CELL SUBSETS AND CYTOKINES — T helper (Th) cell subsets each secrete an array of specific cytokines, which then influence the development and perpetuation of systemic inflammation. Th cells and their cytokines can be categorized into two general subsets, termed Th1 and Th2, which differ in how they affect the immune system. The cytokines generated by Th1 or Th2 cells respectively inhibit the cellular function of the other phenotype [1,2]. Additional cell types, termed Th17 cells and regulatory T cells (T reg), have also been described. Th cell differentiation and function are described in detail separately. (See "The adaptive cellular immune response: T cells and cytokines", section on 'Cytokine profiles and functions of CD4+ T helper cell subsets'.)

Briefly, the following major subsets are important and of particular interest in the regulation of normal immune function and immune-mediated disorders:

Th1 cells – Th1 lymphocytes participate in a broad variety of inflammatory responses, including cell-mediated inflammation in rheumatoid arthritis, psoriasis, psoriatic arthritis, acute allograft rejection, graft-versus-host disease, and others. Some of the proinflammatory mediators produced by Th1 cells include interferon gamma (IFNg), tumor necrosis factor (TNF), and interleukin (IL) 2. IFNg and IL-2 can inhibit Th2 cell proliferation.

Th2 cells – Th2 lymphocytes stimulate antibody production by B cells and augment eosinophil responses. The activation of Th2 cells contributes to the development of chronic graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. A partial list of mediators produced by Th2 includes IL-4, -5, -10, and -13. IL-4 and IL-10 can inhibit Th1 cytokine production.

Th17 cells – Th17 cells differentiate from naïve T cells in response to antigen, transforming growth factor (TGF) beta, IL-6, and IL-23 [3,4]. Th17 cells secrete a cytokine, IL-17, which in concert with other cytokines affects inflammation, cartilage, and bone metabolism [5].

T reg cells – T reg cells function largely to regulate other T cells. They may have critical functions in multiple rheumatic diseases, including giant cell arteritis, granulomatosis with polyangiitis, rheumatoid arthritis, systemic lupus erythematosus, spondyloarthritis, Sjögren's syndrome, and other conditions. T reg cells also differentiate under the influence of antigen and TGF beta, and they have a protective function through IL-10 and TGF beta [5]. While not yet clinically tested as cell-based therapy, their capacity to reduce inflammation and autoimmunity are the subject of interest in this context.

A number of anti-cytokine therapies have been developed as therapeutic agents based in part on these observations.

ANTICYTOKINE APPROACHES — Several specific anticytokine therapies for the treatment of autoimmune diseases have been introduced into clinical practice.

Nomenclature — Abbreviations placed at the ends of the names of therapeutic agents convey specific information relating to their structure [6]:

"-cept" refers to fusion of a receptor to the Fc part of human immunoglobulin G1 (IgG1)

"-mab" indicates a monoclonal antibody (mAb)

"-ximab" indicates a chimeric mAb

"-zumab" indicates a humanized mAb

"-umab" indicates a fully human mAb

In late 2021 (World Health Organization [WHO] Nov 2021), an expanded collection of four suffixes was introduced to accommodate the increasing number of mAbs, to decrease sound-alikes, and to provide information about modifications to the immunoglobulin structure [7]. These suffixes are to be used instead of "mab" for mAbs developed from 2022 onward (see "Overview of therapeutic monoclonal antibodies", section on 'Naming convention for therapeutic mAbs'):

"tug" is used for full-length unmodified immunoglobulins that recognize a single epitope (monospecific)

"bart" is used for full-length monospecific immunoglobulins with engineered constant regions or any point mutation introduced by engineering

"mig" is used for bispecific or multispecific immunoglobulins with any structure

"ment" is used for monospecific immunoglobulin variable region fragments

Types of therapeutic molecules — To downregulate or inhibit the effector functions of cytokines in vivo, three general approaches have been used:

Soluble receptor antagonists – Soluble receptor antagonists can be truncated forms of the cell surface receptor that are devoid of the transmembrane and intracytoplasmic domains. However, these molecules retain binding affinities that are comparable to those of full-length membrane-bound receptors. The prototypical soluble receptor antagonist is etanercept, a fusion protein comprised of the p75 tumor necrosis factor (TNF) receptor linked to the Fc portion of human IgG1. (See 'Etanercept' below.)

Soluble receptor molecules such as etanercept bind their target cytokine while it is in serum, thereby inhibiting the cytokine's ability to interact with its cell surface receptors. Soluble fusion proteins must remain in the circulation for at least several days to achieve their therapeutic effects. The half-life of etanercept is longer than that of the native soluble receptor because the receptor binds tightly to the IgG-Fc [8]. Usually, no neutralizing anti-drug antibodies are elicited by these constructs.

Monoclonal antibodies to cytokines or their receptors – The second approach to the downregulation of cytokine function has been the use of mAbs [9]. mAbs also have a higher affinity for a given cytokine compared with soluble receptors (eg, etanercept) that target the same molecule.

Therapeutic mAbs used to treat patients with rheumatologic diseases typically consist of the Fc portion of human IgG1 (sometimes IgG4) and chimeric, humanized, or fully human Fab fragments. Examples of mAbs employed in the treatment of rheumatic disease are infliximab, adalimumab, ustekinumab, and secukinumab. Certolizumab, a polyethylene glycolated (PEGylated) Fab fragment that does not contain an Fc portion, has also been developed, as have other therapeutic antibodies derived from IgG2 and IgG4. (See 'TNF inhibition' below and 'Ustekinumab' below and 'Secukinumab' below.)

Cell surface receptor antagonist proteins – Recombinant cell surface receptor antagonists are biologically inactive proteins that compete with a cytokine for binding to the cytokine's membrane receptor [10]. Examples of cell surface receptor antagonists in the rheumatic diseases are anakinra and rilonacept, recombinant antagonists of the interleukin (IL) 1 receptor (see 'IL-1 inhibition' below). Another mAb against a receptor is brodalumab, an anti-IL-17 receptor antibody. (See 'IL-17 inhibition' below.)

Receptor antagonists must bind greater than 90 percent of the receptors on the cell surface to be effective. Large doses of the antagonist are required for such an effect.

Another approach, which more indirectly targets an array of cytokines, is the use of orally administered small molecule drugs, produced by traditional manufacturing techniques, which are designed to inhibit selected cytoplasmic protein tyrosine kinases, such as Janus kinase (JAK), which mediates signaling from membrane cytokine receptors. (See 'Kinase inhibition' below.)

BIOLOGIC CYTOKINE INHIBITORS

TNF inhibition — Five tumor necrosis factor (TNF) inhibitors are available for the treatment of rheumatoid arthritis and a number of other rheumatic and other immune-mediated diseases in the United States and worldwide. (See 'Etanercept' below and 'Infliximab' below and 'Adalimumab' below and 'Certolizumab' below and 'Golimumab' below.)

These drugs have been the subject of numerous trials and other studies, including multiple meta-analyses. As an example, a systematic literature review and meta-analysis of TNF-blocking agents for rheumatoid arthritis indicated that these agents used in monotherapy were equally efficacious and similar to methotrexate regarding clinical signs. When used in combination with methotrexate, they were better than methotrexate alone [11]. Thus, the combination of a TNF blocker and methotrexate was superior to either methotrexate or a TNF blocker alone, and the TNF blockers were relatively safe compared with methotrexate. The use and evidence for the efficacy of these agents in rheumatoid arthritis and other disorders are described in detail separately in the UpToDate topics on treatment of individual diseases, including rheumatoid arthritis, psoriatic arthritis and psoriasis, spondyloarthritis, inflammatory bowel disease, and others. (See appropriate topic reviews.)

The potential adverse effects of the TNF inhibitors are also described in detail separately. (See "Tumor necrosis factor-alpha inhibitors: An overview of adverse effects" and "Tumor necrosis factor-alpha inhibitors: Risk of malignancy" and "Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections" and "Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases".)

Biosimilar forms of several TNF inhibitors have become commercially available in some countries, and additional biosimilar agents are in development. (See 'Biosimilars for biologic agents' below.)

Etanercept — Etanercept is a soluble p75 TNF receptor fusion protein that consists of two p75 TNF receptors bound to the Fc portion of immunoglobulin G (IgG). Thus, the medication is bivalent (one etanercept molecule binds two TNF molecules). Etanercept is administered once or twice weekly via subcutaneous injection.

Etanercept is used for the treatment of a number of forms of inflammatory arthritis and other conditions, including juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. However, etanercept is not effective for ulcerative colitis and Crohn disease. (See appropriate topic reviews on the treatment of specific diseases.)

Biosimilars of etanercept have received regulatory approval in Europe, South Korea, and other countries [12]. (See 'Biosimilars for biologic agents' below.)

Infliximab — Infliximab is a chimeric monoclonal antibody (mAb) directed against TNF. The term "chimeric" refers to the use of both murine and human components of the drug. With infliximab, the kappa chain variable region (VK) and heavy chain variable region (VH) domains of the antigen-binding portion of the molecule are murine, and the constant Fc domain is human. Infliximab is administered via intravenous infusion approximately every six weeks once a steady state has been achieved.

The European Medicines Agency (EMA) approved a subcutaneous version of a biosimilar infliximab, which is also available in Canada and Korea, but not in the United States [13].

Infliximab is effective for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn disease, and ulcerative colitis. (See appropriate topic reviews on the treatment of specific diseases.)

Biosimilar forms of infliximab, such as infliximab-dyyb, have been approved in a number of countries worldwide, with all the indications of the legacy (originator) compound [12]. (See 'Biosimilars for biologic agents' below.)

Adalimumab — Adalimumab is a recombinant fully human mAb that is administered subcutaneously rather than by intravenous infusion. The recommended interval between administrations is every two weeks. Adalimumab is associated with a lower risk of anti-drug antibody formation compared with infliximab, possibly by virtue of its fully human construction. Nevertheless, anti-drug antibodies occur upon treatment with adalimumab. They are directed against the idiotype and can be neutralizing. (See "Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases", section on 'Adalimumab-induced human anti-human antibodies'.)

Adalimumab has been approved for use in rheumatoid arthritis, plaque psoriasis, Crohn disease, pediatric Crohn disease, ulcerative colitis, psoriatic arthritis, hidradenitis suppurativa, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, and noninfectious intermediate, posterior, and panuveitis (see appropriate topic reviews on the treatment of specific diseases). Adalimumab biosimilars have been approved in numerous countries and regions, including in India [12], Canada, Europe [14], and the United States [15].

Certolizumab — Certolizumab pegol is a humanized anti-TNF-alpha antibody Fab' fragment that is chemically linked to polyethylene glycol. The medication neutralizes membrane-associated and soluble TNF-alpha. Certolizumab pegol is administered every two weeks by subcutaneous injection, and dosing at four-week intervals can be effective in some patients for maintenance therapy.

Certolizumab pegol is formally approved in the United States for use in Crohn disease and rheumatoid arthritis, as well as psoriatic arthritis and ankylosing spondylitis, and it has been used in uveitis and ulcerative colitis. Like the other TNF inhibitors it is available worldwide. (See appropriate topic reviews on the treatment of specific diseases.)

In addition, the EMA has approved a label change for certolizumab pegol, making it the first anti-TNF for potential use in women with chronic rheumatic disease during both pregnancy and breastfeeding, based on two trials [16,17]. (See "Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Tumor necrosis factor inhibitors'.)

Golimumab — Golimumab is a human IgG1 kappa mAb specific for human TNF-alpha that neutralizes TNF-alpha activity. Golimumab binds to both the soluble and transmembrane bioactive forms of human TNF-alpha. It is administered once monthly by subcutaneous injection.

Golimumab has been available for use in patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis in a number of countries. (See appropriate topic reviews on the treatment of specific diseases.)

IL-1 inhibition — Interleukin (IL) 1 inhibitors such as anakinra are available commercially for use in patients with rheumatoid arthritis and other forms of inflammatory arthritis. However, their relatively modest effect on inflammatory arthritis in rheumatoid arthritis compared with other biologic agents, such as the TNF inhibitors, has resulted in their being used only rarely for this disease. These agents are also used in systemic-onset juvenile idiopathic arthritis and adult-onset Still's disease, as well as other conditions. The biology, adverse effects, and other factors related to the various IL-1 inhibitors are discussed in detail separately. (See "Interleukin 1 inhibitors: Biology, principles of use, and adverse events".)

Anakinra and two other IL-1 inhibitors, canakinumab and rilonacept, through their effect on the inflammasome (a critical mediator of autoinflammatory conditions), are effective for the treatment of autoinflammatory conditions such as cryopyrin-associated periodic syndromes (CAPS), TNF receptor-1 associated periodic syndrome (TRAPS), and familial Mediterranean fever, and are used to treat these conditions. (See "Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)" and "Cryopyrin-associated periodic syndromes and related disorders" and "Management of familial Mediterranean fever", section on 'Interleukin 1 inhibition'.)

IL-1 inhibition also has a role in the treatment of selected patients with acute gouty arthritis, as well as pseudogout. (See "Treatment of gout flares", section on 'Resistant disease or unable to take other therapies' and "Treatment of calcium pyrophosphate crystal deposition (CPPD) disease", section on 'Resistant disease'.)

A variety of approaches to IL-1 inhibition, including receptor antagonism and IL-1 binding, have been employed.

Anakinra — Anakinra is a recombinant human IL-1 receptor antagonist (rHuIL-1Ra), which unlike the native protein is not glycosylated and has an additional N-terminal methionine. Anakinra is available for the treatment of rheumatoid arthritis but is significantly less potent in most patients with rheumatoid arthritis than TNF inhibitors [18,19]. Unlike conventional disease-modifying antirheumatic drugs (DMARDs; eg, methotrexate), anakinra is not recommended in a combination regimen with a TNF inhibitor or other biologic agents because of an increased frequency of serious adverse events, including serious infections [20,21]. (See "Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'Resistant to standard therapies'.)

Anakinra may be more effective in the treatment of autoinflammatory conditions, including TRAPS (see "Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)"). It is also used for the treatment of systemic juvenile idiopathic arthritis and adult-onset Still's disease, and in selected patients with recurrent pericarditis (see "Systemic juvenile idiopathic arthritis: Treatment" and "Treatment of adult-onset Still's disease" and "Recurrent pericarditis", section on 'Other immune therapy'). In the European Union, anakinra is approved to treat signs and symptoms of rheumatoid arthritis in combination with methotrexate in patients who have not responded adequately to methotrexate alone, and CAPS [22].

Canakinumab — Canakinumab, an anti-IL-1beta (anti-IL-1b) mAb with a longer half-life than anakinra, has also been employed in autoinflammatory conditions and in settings in which IL-1 inhibition is beneficial (eg, acute gout in which contraindications to conventional therapies exist) [23].

In the European Union, canakinumab is approved for four types of periodic fever syndromes in adults and children aged two and above: CAPS, TRAPS, hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), and familial Mediterranean fever; as well as for adult-onset Still's disease; systemic juvenile idiopathic arthritis (Still's disease; in children, aged two and above); and gouty arthritis [24].

Rilonacept — Rilonacept is a human IgG1 Fc antibody with bispecific arms; these bind IL-1b. Like the other IL-1 inhibitors, it is available for use in patients with CAPS and related conditions such as the Muckle-Wells syndrome, another rare autoinflammatory disease. Although the manufacturer of rilonacept applied for US Food and Drug Administration (FDA) approval for gout, this approval was not granted. Nevertheless, like the other IL-1 inhibitors, it is sometimes used in this disease. Rilonacept is also approved for use in the United States for recurrent pericarditis. (See "Cryopyrin-associated periodic syndromes and related disorders", section on 'Rilonacept' and "Recurrent pericarditis", section on 'Interleukin 1 inhibitors'.)

IL-6 inhibition — IL-6 has both proinflammatory and antiinflammatory effects and has been successfully targeted for the treatment of rheumatoid arthritis and other rheumatic diseases [25]. The cytokine activates T cells, B cells, macrophages, and osteoclasts and is a pivotal mediator of the hepatic acute phase response. In concert with TNF-alpha and IL-1, IL-6 promotes vascular endothelial growth factor (VEGF) and metalloproteinase production [26].

IL-6 binds to both soluble and membrane-bound receptors and leads to the transduction of intracellular signals through the interaction of this complex with gp130, mediating gene activation and a wide range of biologic activities [26,27].

The biology, principles of use, and adverse effects of therapeutic IL-6 inhibitors are described in detail separately. (See "Interleukin 6 inhibitors: Biology, principles of use, and adverse effects".)

Tocilizumab — Tocilizumab is a humanized anti-human IL-6 receptor antibody of the IgG1 subclass. The medication is made by grafting the complementarity determining regions of a mouse anti-human IL-6 receptor mAb onto human IgG1. Tocilizumab binds to both the membrane-bound and soluble forms of human IL-6 receptor (IL-6R), thereby inhibiting the action of the cytokine/receptor complex and interfering with the cytokine's effects.

Tocilizumab is available in many countries for use in patients with rheumatoid arthritis; in some countries, it is also available for juvenile idiopathic arthritis and Castleman disease. (See "Systemic juvenile idiopathic arthritis: Treatment", section on 'Interleukin 6 inhibitors' and "HHV-8-negative/idiopathic multicentric Castleman disease", section on 'IL-6 inhibitors' and "Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'IL-6 inhibitor therapies' and "Treatment of rheumatoid arthritis in adults resistant to initial conventional synthetic (nonbiologic) DMARD therapy", section on 'Methotrexate plus IL-6 inhibitor/IL-6 inhibitor monotherapy'.)

Tocilizumab has also shown benefit in giant cell arteritis and is approved for this indication [28] (see "Treatment of giant cell arteritis", section on 'Tocilizumab'). It is also used in patients with coronavirus disease 2019 (COVID-19) and patients with cytokine release syndrome associated with chimeric antigen receptor (CAR)-T cell therapy. (See "COVID-19: Management in hospitalized adults", section on 'IL-6 pathway inhibitors (eg, tocilizumab)' and "Cytokine release syndrome (CRS)", section on 'CAR-T cell-associated CRS'.)

Sarilumab — Another human mAb, sarilumab, is a fully human recombinant mAb of the IgG1 subclass that binds to the IL-6R and acts as an IL-6R antagonist. It is directed against both the membrane-bound and soluble IL-6R and is available in the United States and the European Union for the treatment of rheumatoid arthritis. It is administered by subcutaneous injection every two weeks [29-31].

IL-17 inhibition — IL-17, which is produced by Th17 cells, amplifies production of multiple cytokines and stimulates keratinocytes, synoviocytes, macrophages, fibroblasts, and neutrophils [32]. Antibodies that target the IL-17 pathways have been developed and are marketed for the treatment of several conditions in which the IL-17 pathway has a role, including psoriasis and psoriatic arthritis, spondyloarthritis, and other immune-mediated diseases.

Secukinumab — Secukinumab is a fully human IgG1 kappa mAb against IL-17 [33]. It is commercially available for use in psoriasis and psoriatic arthritis and for ankylosing spondylitis and nonradiographic axial spondyloarthritis, and is being investigated in uveitis. Secukinumab is administered by monthly subcutaneous injection after several loading doses [34]. It has also been used in uveitis [33]. Its efficacy in rheumatoid arthritis (for which it has not been approved) appears to be modest, and comparatively less than in these other conditions based upon limited study [35]. (See "Treatment of psoriasis in adults", section on 'Secukinumab' and "Treatment of psoriatic arthritis", section on 'Secukinumab' and "Treatment of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults".)

Ixekizumab — Ixekizumab, a humanized mAb against IL-17A, has been granted FDA and EMA approval for the treatment of psoriasis and has been effective for psoriatic arthritis as well. It has also been granted EMA approval for psoriatic arthritis. (See "Treatment of psoriatic arthritis", section on 'Ixekizumab'.)

IL-12/23 blockade

Ustekinumab — Ustekinumab is a human IgG1 kappa mAb that binds to the p40 subunit shared by IL-12 and IL-23. It is available for use in the treatment of psoriasis and psoriatic arthritis [36]. It is administered every 12 weeks by subcutaneous injection after several loading doses. (See "Treatment of psoriatic arthritis", section on 'Ustekinumab' and "Treatment of psoriasis in adults", section on 'Ustekinumab'.)

Ustekinumab interferes with the binding of the proinflammatory cytokines IL-12 and IL-23 to their cell surface receptors. Biologic effects of IL-12 and IL-23 include natural killer (NK) cell activation, CD4+ T-cell differentiation and activation. Ustekinumab also interferes with the expression of monocyte chemotactic protein (MCP)-1, TNF-alpha, interferon-inducible protein-10 (IP-10), and IL-8. (See "Treatment of psoriatic arthritis", section on 'Ustekinumab' and "Treatment of psoriasis in adults", section on 'Ustekinumab'.)

Ustekinumab is also approved by the EMA for the treatment of adult patients with moderately to severely active Crohn disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-alpha antagonist or have medical contraindications to such therapies [37].

Guselkumab — Guselkumab is a human IgG1 mAb directed against the p19 subunit of IL-23 and is thus specific for IL-23, not binding to IL-12. It is highly efficacious in psoriasis and also works in psoriatic arthritis. It has been approved for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. It has been approved by the FDA and EMA for use in psoriatic arthritis.

Risankizumab — Risankizumab is a humanized IgG1 mAb directed against the p19 subunit of IL-23 [38-40]. It was approved by the FDA and EMA for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and subsequently approved for the treatment of psoriatic arthritis. It is administered subcutaneously 4 weeks apart for the first 2 doses, then every 12 weeks, and may be administered alone or in combination with conventional synthetic DMARDs.

COSTIMULATION BLOCKADE — A biologic agent, abatacept, that targets a key pathway in T-cell costimulation is available for use in rheumatoid arthritis and is under study in other rheumatic diseases. CD28 and CTLA-4 (CD152) are important in the regulation of T-cell activation and function; they help control some of the cross-talk between T cells, on which they are primarily expressed, and antigen-presenting cells, on which they interact with their ligands, CD80 and CD86 (also termed B7-1 and B7-2) [41]. CD28 binding has been found to decrease the activity of regulatory T cells (T reg) and to increase T effector cell activity, while CTLA-4 may, by contrast, ultimately activate T effector cells without suppressing T reg activity [42]. Thus, targeting of these pathways can impact immune function. (See "Transplantation immunobiology", section on 'T cell costimulation'.)

Abatacept — Abatacept is a soluble fusion protein comprising CTLA-4 and the Fc portion of immunoglobulin G1 (IgG1) (CTLA4-Ig). Abatacept is available for use in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. Abatacept can be administered by either weekly subcutaneous injection or by monthly intravenous infusion following several loading doses. (See "Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'Abatacept' and "Treatment of rheumatoid arthritis in adults resistant to initial conventional synthetic (nonbiologic) DMARD therapy", section on 'Methotrexate plus abatacept'.)

Abatacept prevents CD28 from binding to its counter-receptor, CD80/CD86, due to its higher affinity for CD80/CD86. This prevents the suppression of T reg activity and prevents increased T effector cell activity [42]. Administration of CTLA4-Ig or successful transfer of its gene also prevents or ameliorates collagen-induced arthritis in mice, and it is beneficial in transplantation models [43,44].

B-CELL DEPLETION AND INHIBITION — Biologic agents that can deplete B cells (eg, rituximab) or inhibit factors that activate B cells (belimumab) are used for the treatment of a range of rheumatic and other diseases. In addition to their central role in antibody production, B cells present antigen to T cells, activate T cells, and promote the production of proinflammatory cytokines, including interleukin (IL) 1, IL-4, IL-6, IL-8, IL-10, and IL-12; tumor necrosis factor (TNF)-alpha; vascular endothelial growth factor (VEGF); monocyte chemotactic protein (MCP); and macrophage migration inhibitory factor (MIF) [45]. (See "Normal B and T lymphocyte development".)

Rituximab — Rituximab, a chimeric immunoglobulin G1 (IgG1) monoclonal antibody (mAb), is used to treat lymphoproliferative disorders and several rheumatic diseases. It eliminates CD20-positive B cells, induces complement mediated cytotoxicity, and stimulates apoptosis but has little and/or nonspecific effects on autoantibody titers. It is probable that some combination of these effects account for its activity in autoimmune disease [46]. It is usually administered as a short series of typically two or four intravenous infusions every four to six months or at longer intervals as needed. (See "Rituximab: Principles of use and adverse effects in rheumatoid arthritis" and "Initial treatment of advanced stage diffuse large B cell lymphoma", section on 'Incorporation of rituximab'.)

In addition to treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia, rituximab is indicated for treating rheumatoid arthritis and granulomatosis with polyangiitis and microscopic polyangiitis. It has also been used in systemic lupus erythematosus, systemic sclerosis, and other forms of vasculitis as well as myositis, although it is not formally approved by regulatory agencies for any of these other conditions. (See "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy".)

Implications of rituximab use in patients during the coronavirus disease 2019 (COVID-19) pandemic are described separately. (See "COVID-19: Care of adult patients with systemic rheumatic disease".)

Belimumab — Belimumab is an anti-B lymphocyte stimulator (BLyS) mAb which binds to soluble BLyS, preventing its binding and stimulation of B cells [45]. It is available for use for the treatment of systemic lupus erythematosus and is being studied in other conditions, such as Sjögren syndrome. Belimumab is administered by intravenous infusion every four weeks after therapy is initiated with several more frequent loading doses. It is also available for subcutaneous injections. (See "Overview of the management and prognosis of systemic lupus erythematosus in adults".)

GM-CSF LIGAND AND RECEPTOR ALPHA CHAIN INHIBITORS — Both the granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor and GM-CSF itself have been targets of inhibitory monoclonal antibodies (mAbs). Mavrilimumab, a human mAb targeting the GM-CSF receptor-alpha, has been under investigation for use in patients with active rheumatoid arthritis (RA) [47-50] and is being investigated in giant cell arteritis [51]. Otilimab is an anti-GM-CSF mAb that is also under study for patients with RA [52,53].

GM-CSF is a proinflammatory cytokine involved in pathogenesis of RA through its capacity to promote the activation, differentiation, and survival of macrophages, dendritic cells, and neutrophils. It is upregulated in synovial tissue and circulating cells from patients with RA, and there is interest in the therapeutic utility of targeting the GM-CSF receptor and other colony-stimulating factors in patients with RA. It has also been implicated in the pathogenesis of GCA [54].

BIOSIMILARS FOR BIOLOGIC AGENTS — Copies of biologic agents, including several of the tumor necrosis factor (TNF) inhibitors, rituximab, and other therapeutic molecules, have been marketed and are under development for use in the rheumatic diseases. A "biosimilar" is a copy that is similar but not identical to the legacy product; a biosimilar can be marketed after the legacy (ie, reference or originator) product is no longer under patent protection. A biosimilar is defined by the World Health Organization (WHO) as a "biotherapeutic product which is similar in terms of quality, safety, and efficacy to an already licensed reference biotherapeutic product" [55]. "Similarity" is defined as the "absence of a relevant difference in the parameter of interest."

The regulatory requirements for biosimilars differ between countries and regions around the world [56,57]. A biosimilar, unlike a "biomimic" or "biocopy," which are medications marketed in some countries, has the same primary amino acid sequence as the reference product and has undergone rigorous analytic and clinical testing in comparison with its reference product [58].

The American College of Rheumatology (ACR) has issued a "white paper" on biosimilars in rheumatology, which reviews the nomenclature, science, clinical, and economic aspects of these agents [59]. Importantly, the report also describes the regulatory pathway for approval of biosimilars in the United States, including the process of extrapolation of indications. The ACR report notes the "scientific rigor" with which the US Food and Drug Administration (FDA) and other regulatory agencies outside of the United States have evaluated these agents; the authors of the report further suggest that health care providers should incorporate biosimilars, where appropriate, into treatment regimens for patients with rheumatologic diseases.

A 2016 systematic review described the results of 19 observational studies and clinical trials that compared biosimilar TNF-alpha inhibitors with their reference biologic products, including infliximab, etanercept, and adalimumab; the research provided evidence supporting the efficacy and safety of these agents [60]. Pharmacokinetic measurements for the respective biosimilar drugs and their reference products were within defined equivalence margins, and similar clinical responses and adverse events were found for the tested products and their reference drugs. There were eight phase 1 randomized trials, seven of which involved healthy volunteers, and one of which involved patients with ankylosing spondylitis; five phase 3 randomized trials, involving patients with rheumatoid arthritis; and six observational studies, involving patients with rheumatoid arthritis or inflammatory bowel disease. Two studies documented immunologic cross-reactivity between products, and similar efficacy and safety were observed in four cohort studies in which patients were switched from the reference product to a biosimilar medication.

Examples of biosimilar agents include:

Infliximab-dyyb – Infliximab-dyyb is an example of a biosimilar. The immunoglobulin G1 (IgG1) chimeric human-murine monoclonal antibody (mAb), CT-P13, now termed "infliximab-dyyb" in the United States, was developed as an anti-TNF-alpha mAb biosimilar to the original ("reference product" or "innovator" or "legacy") infliximab that first became commercially available in 1999 for the treatment of rheumatoid arthritis [61,62]. Infliximab-dyyb has an identical amino acid sequence to infliximab and is produced in the same type of cell line; it exhibits highly similar in vitro and in vivo pharmacodynamics, binding specificities and affinities, and other biologic and pharmacologic characteristics [61,62].

Infliximab-dyyb has shown equivalent clinical efficacy by multiple response measures to the innovator infliximab in a small number of randomized clinical trials in patients with rheumatoid arthritis and in patients with ankylosing spondylitis, without any differences detected in immunogenicity or safety between the two agents [61]. The drug has been available in South Korea since 2012 [63].

The worldwide availability of this biosimilar for infliximab is increasing, and it is now available in over 70 countries [56]. The availability of each of these agents and approved indications for their use will depend upon regulatory requirements in different regions and local patent laws and patent expiration dates [64]. In Europe and the United States, this agent is approved for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis, Crohn disease, and ulcerative colitis [65,66].

Other agents – Additional biosimilars of biologic agents used for the treatment of rheumatic disease have been approved for use or are in active clinical development, including further biosimilars for infliximab and additional biosimilars to other commercially available biologic agents, including etanercept [67], adalimumab, and rituximab [56]. Several of these have been approved by regulatory agencies in several countries and regions, and their availability is growing.

Commercially available products that have received regulatory designation as biosimilar (eg, infliximab, etanercept, and adalimumab) in the United States, Canada, and some other countries are described in the drug information monograph (Lexicomp) included within UpToDate for the legacy (originator) biologic agent. (See "Infliximab (including biosimilars): Drug information" and "Etanercept (including biosimilars available in Canada): Drug information" and "Adalimumab (including biosimilars): Drug information".)

An updated list of FDA-approved biologic products and biosimilars is available through the FDA Center for Drug Evaluation and Research [68], and updated information regarding European Medicines Agency (EMA)-approved biosimilars is also available [69,70].

KINASE INHIBITION — Several pathways that mediate receptor signal transduction have been targeted by the use of small molecules that are kinase inhibitors [71,72]. These are highly targeted molecules that are relatively simple chemical compounds; unlike therapeutic agents made by recombinant DNA techniques (and thus termed "biologics"), such as monoclonal antibodies (mAbs) and soluble truncated membrane receptors, the kinase inhibitors are not proteins and hence are not biologics. An advantage of these agents is that they can be orally administered. The Janus kinases (JAK) are cytoplasmic protein tyrosine kinases that are critical for signal transduction to the nucleus from the common gamma chain of the plasma membrane receptors for interleukin (IL) 2, IL-4, IL-7, IL-9, IL-15, and IL-21. Four of these agents have become available for clinical use (see 'Tofacitinib' below and 'Baricitinib' below and 'Upadacitinib' below and 'Peficitinib' below and "Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'Tofacitinib' and "Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'Baricitinib'), and others are in development.

The biology, principles of use, and adverse effects of the JAK inhibitors are discussed in detail separately. (See "Janus kinase inhibitors for rheumatologic and other inflammatory disorders: Biology, principles of use, and adverse effects".)

The relative safety of these JAK inhibitors appears similar to that of biologic disease-modifying antirheumatic drugs (DMARDs), including increased risk of infections and liver function test abnormalities; additional concerns that require attention in clinical use include neutropenia, hyperlipidemia, and possible increased serum creatinine. There is a signal of an increased occurrence of herpes zoster, particularly in patients from Korea and Japan as shown for tofacitinib.

Tofacitinib — Tofacitinib is a small, orally active drug available in the United States, the European Union, and many other countries that preferentially inhibits JAK-1 and JAK-3, although it is active on all the JAK isoforms. It reduced signs and symptoms of disease activity in patients with rheumatoid arthritis in a series of randomized trials, including patients with active rheumatoid arthritis and inadequate responses to methotrexate, other traditional (nonbiologic) DMARDs, and tumor necrosis factor (TNF) inhibitors. The degree of benefit appeared at least comparable to the TNF inhibitor, adalimumab, with which it was directly compared. (See "Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'Tofacitinib'.)

The biology, principles of use, and adverse effects of tofacitinib and the other JAK inhibitors are discussed in detail separately. (See "Janus kinase inhibitors for rheumatologic and other inflammatory disorders: Biology, principles of use, and adverse effects".)

Baricitinib — Baricitinib is a small, orally active drug available in the United States (2 mg/day), the European Union (2 and 4 mg/day), and other countries, that preferentially inhibits JAK-1 and JAK-2. It reduced signs and symptoms of disease activity in patients with rheumatoid arthritis in a series of randomized trials, including patients with active rheumatoid arthritis and inadequate responses to methotrexate, other traditional (ie, conventional or nonbiologic) DMARDs, and TNF inhibitors. (See "Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'Baricitinib'.)

Upadacitinib — Upadacitinib is a JAK inhibitor available for use in patients with active rheumatoid arthritis and an inadequate response to methotrexate and for psoriatic arthritis. It is preferentially directed against the JAK-1 molecule and administered as a once-daily oral medication of 15 mg. Further data are required to determine whether JAK-1 selectivity confers a different efficacy and safety profile compared with the less selective agents. (See "Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'Upadacitinib'.)

Peficitinib — Peficitinib is an orally bioavailable, once-daily JAK inhibitor for the treatment of patients with rheumatoid arthritis with an inadequate response to DMARDs, including methotrexate. Peficitinib is a pan-JAK inhibitor that inhibits JAK-1, JAK-2, JAK-3, and tyrosine kinase 2 [73,74]. It has been approved in Japan and Korea.

Filgotinib — Filgotinib is an oral, selective JAK-1 inhibitor that was efficacious in phase 2 and 3 trials in patients with rheumatoid arthritis. Filgotinib 200 or 100 mg daily with conventional synthetic DMARDs or as monotherapy demonstrated rapid, significant improvements in disease activity versus placebo [75-79]. It has been approved by the European Medicines Agency (EMA).

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Side effects of anti-inflammatory and anti-rheumatic drugs".)

SUMMARY

Biologic targeting for rheumatologic disease treatment – The major biologic approaches to treatment of the rheumatologic diseases include agents that (see 'Anticytokine approaches' above):

Interfere with cytokine function

Inhibit the "second signal" required for T-cell activation

Deplete B cells

Biologic therapeutic agents for rheumatologic disease – The following biologic treatment strategies are employed in rheumatic disease:

Tumor necrosis factor (TNF) inhibition (see 'TNF inhibition' above)

Interleukin (IL) 1 inhibition (see 'IL-1 inhibition' above)

IL-6 inhibition (see 'IL-6 inhibition' above)

IL-17 inhibition (see 'IL-17 inhibition' above)

IL-12/23 inhibition (see 'IL-12/23 blockade' above)

Costimulation blockade (see 'Costimulation blockade' above)

B-cell depletion and inhibition of B-cell activation (see 'B-cell depletion and inhibition' above)

Biosimilars – Copies of biologic agents that are no longer under patent protection are becoming available for use in multiple countries. These medications have the same amino acid sequences as the original reference molecules, and the regulatory regimens require these biosimilar agents to be highly similar in terms of quality, safety, and efficacy to the already-licensed reference biotherapeutic product. (See 'Biosimilars for biologic agents' above.)

Janus kinase inhibitorsTofacitinib, baricitinib, upadacitinib, peficitinib, and filgotinib are orally administered, highly targeted, small molecule pharmaceutical agents that inhibit Janus kinases (JAK), which are cytoplasmic protein tyrosine kinases that mediate signaling from an array of multiple cytokine receptors to the nucleus. Their therapeutic benefits and adverse effects in rheumatic diseases are generally similar to the biologic agents. (See 'Kinase inhibition' above.)

ACKNOWLEDGMENT — The editorial staff at UpToDate would like to acknowledge John H Stone, MD, MPH, who contributed to an earlier version of this topic review.

  1. Mosmann TR, Moore KW. The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today 1991; 12:A49.
  2. Zhu J, Yamane H, Cote-Sierra J, et al. GATA-3 promotes Th2 responses through three different mechanisms: induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors. Cell Res 2006; 16:3.
  3. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235.
  4. Bacchetta R, Gambineri E, Roncarolo MG. Role of regulatory T cells and FOXP3 in human diseases. J Allergy Clin Immunol 2007; 120:227.
  5. Koenders MI, Joosten LA, van den Berg WB. Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis. Ann Rheum Dis 2006; 65 Suppl 3:iii29.
  6. Lamberg L. A host of novel agents for treating psoriasis, psoriatic arthritis stir interest. JAMA 2003; 289:2779.
  7. Balocco R, De Sousa Guimaraes Koch S, Thorpe R, et al. New INN nomenclature for monoclonal antibodies. Lancet 2022; 399:24.
  8. Heaney ML, Golde DW. Soluble cytokine receptors. Blood 1996; 87:847.
  9. Bendtzen K, Hansen MB, Ross C, et al. Cytokines and autoantibodies to cytokines. Stem Cells 1995; 13:206.
  10. Arend WP. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest 1991; 88:1445.
  11. Aaltonen KJ, Virkki LM, Malmivaara A, et al. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 2012; 7:e30275.
  12. Dörner T, Kay J. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol 2015; 11:713.
  13. Remsima. European Medicines Agency (EMA) Summary of product characteristics. Last updated January 12, 2020. European Medicines Agency. (Available online at www.ema.europa.eu/en/documents/product-information/remsima-epar-product-information_en.pdf).
  14. Bellinvia S, Cummings JRF, Ardern-Jones MR, Edwards CJ. Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence. BioDrugs 2019; 33:241.
  15. HIGHLIGHTS OF PRESCRIBING INFORMATION for YUSIMRY (adalimumab-aqvh) injection, for subcutaneous use https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761216s000lbl.pdf (Accessed on February 23, 2022).
  16. Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis 2018; 77:228.
  17. Clowse ME, Förger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis 2017; 76:1890.
  18. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148:124.
  19. Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev 2009; :CD005121.
  20. Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol Suppl 2002; 65:33.
  21. Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50:1412.
  22. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000363/human_med_000874.jsp&mid=WC0b01ac058001d124 (Accessed on July 10, 2018).
  23. Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012; 71:1839.
  24. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001109/human_med_000826.jsp&mid=WC0b01ac058001d124 (Accessed on July 10, 2018).
  25. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993; 54:1.
  26. Okuda Y. Review of tocilizumab in the treatment of rheumatoid arthritis. Biologics 2008; 2:75.
  27. Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol 1998; 16:249.
  28. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000955/human_med_001042.jsp&mid=WC0b01ac058001d124 (Accessed on July 10, 2018).
  29. Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Arthritis Rheumatol 2015; 67:1424.
  30. Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis 2017; 76:840.
  31. Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol 2017; 69:277.
  32. Waite JC, Skokos D. Th17 response and inflammatory autoimmune diseases. Int J Inflam 2012; 2012:819467.
  33. Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 2013; 72 Suppl 2:ii116.
  34. Ramiro S, Smolen JS, Landewé R, et al. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2016; 75:490.
  35. Genovese MC, Durez P, Richards HB, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 2013; 72:863.
  36. Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 2014; 73:1000.
  37. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000958/human_med_001065.jsp&mid=WC0b01ac058001d124 (Accessed on July 10, 2018).
  38. Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2015; 136:116.
  39. Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis 2022; 81:225.
  40. Östör A, Van den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis 2022; 81:351.
  41. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14:233.
  42. Dilek N, Poirier N, Hulin P, et al. Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells. PLoS One 2013; 8:e83139.
  43. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381:434.
  44. Quattrocchi E, Dallman MJ, Feldmann M. Adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune arthritis. Arthritis Rheum 2000; 43:1688.
  45. Engel P, Gómez-Puerta JA, Ramos-Casals M, et al. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol Rev 2011; 63:127.
  46. Pateinakis P, Pyrpasopoulou A. CD20+ B cell depletion in systemic autoimmune diseases: common mechanism of inhibition or disease-specific effect on humoral immunity? Biomed Res Int 2014; 2014:973609.
  47. Burmester GR, Feist E, Sleeman MA, et al. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Ann Rheum Dis 2011; 70:1542.
  48. Burmester GR, McInnes IB, Kremer J, et al. A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Ann Rheum Dis 2017; 76:1020.
  49. Burmester GR, McInnes IB, Kremer JM, et al. Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis. Arthritis Rheumatol 2018; 70:679.
  50. Weinblatt ME, McInnes IB, Kremer JM, et al. A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis. Arthritis Rheumatol 2018; 70:49.
  51. Cid MC, Unizony SH, Blockmans D, et al. Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2022; 81:653.
  52. Crotti C, Agape E, Becciolini A, et al. Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects. Drugs 2019; 79:1741.
  53. Behrens F, Tak PP, Østergaard M, et al. MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis 2015; 74:1058.
  54. Corbera-Bellalta M, Alba-Rovira R, Muralidharan S, et al. Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis. Ann Rheum Dis 2022; 81:524.
  55. World Health Organization. Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products. Geneva, 2009. http://www.who.int/biologicals/areas/biological_ (Accessed on September 28, 2013).
  56. Dörner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis 2016; 75:974.
  57. Gherghescu I, Delgado-Charro MB. The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA. Pharmaceutics 2020; 13.
  58. Kay J. Editorial: Biosimilars: New or Déjà Vu? Arthritis Rheumatol 2016; 68:1049.
  59. Bridges SL Jr, White DW, Worthing AB, et al. The Science Behind Biosimilars: Entering a New Era of Biologic Therapy. Arthritis Rheumatol 2018; 70:334.
  60. Chingcuanco F, Segal JB, Kim SC, Alexander GC. Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics: A Systematic Review. Ann Intern Med 2016; 165:565.
  61. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72:1613.
  62. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013; 72:1605.
  63. Kim SC, Choi NK, Lee J, et al. Brief Report: Utilization of the First Biosimilar Infliximab Since Its Approval in South Korea. Arthritis Rheumatol 2016; 68:1076.
  64. Kay J, Smolen JS. Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis 2013; 72:1589.
  65. European Medicines Agency: Inflectra (infliximab). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002778/human_med_001677.jsp&mid=WC0b01ac058001d124 (Accessed on June 26, 2016).
  66. FDA News Release: FDA approves Inflectra, a biosimilar to Remicade. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494227.htm.
  67. Emery P, Vencovský J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2017; 76:51.
  68. US FDA Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm411418.htm (Accessed on April 06, 2018).
  69. Biosimilars in the EU. https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf (Accessed on January 14, 2022).
  70. Generic and biosimilar initiative. Biosimilars approved in Europe https://gabionline.net/biosimilars/general/biosimilars-approved-in-europe (Accessed on January 14, 2022).
  71. Bonilla-Hernán MG, Miranda-Carús ME, Martin-Mola E. New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors. Rheumatology (Oxford) 2011; 50:1542.
  72. Kerschbaumer A, Smolen JS, Nash P, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. RMD Open 2020; 6.
  73. Takeuchi T, Tanaka Y, Tanaka S, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann Rheum Dis 2019; 78:1305.
  74. Nakayamada S, Kubo S, Iwata S, Tanaka Y. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis. BioDrugs 2016; 30:407.
  75. Westhovens R, Rigby WFC, van der Heijde D, et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis 2021; 80:727.
  76. Genovese MC, Kalunian K, Gottenberg JE, et al. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. JAMA 2019; 322:315.
  77. Westhovens R, Taylor PC, Alten R, et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis 2017; 76:998.
  78. Vanhoutte F, Mazur M, Voloshyn O, et al. Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials. Arthritis Rheumatol 2017; 69:1949.
  79. Kavanaugh A, Kremer J, Ponce L, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis 2017; 76:1009.
Topic 7966 Version 29.0

References